Maintenance Therapy in Mantle Cell Lymphoma

Video

This video reviews different strategies for maintenance therapy in mantle cell lymphoma, as well as highlighting upcoming research in this setting.

In this video, Brad S. Kahl, MD, of the Washington University School of Medicine in St. Louis, Missouri, reviews the goals of maintenance therapy for the treatment of patients with mantle cell lymphoma, as well as highlighting different maintenance strategies and upcoming research in this setting.

Kahl spoke on this topic during an education session at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, held last month in Chicago.

Related Videos
Resolving disparities within the blood cancer space is a matter of “access to excellent healthcare,” according to Usama Gergis, MD, MBA.
Discrepancies in patients with blood cancer who are eligible for but do not undergo hematopoietic stem cell transplant have been observed not only for Black patients, but Hispanic, Asian, and White patients as well, according to Usama Gergis, MD, MBA.
Expert on myelofibrosis
Expert on myelofibrosis
Experts on myelofibrosis
Expert on myelofibrosis
Expert on myelofibrosis
Expert on myelofibrosis
Related Content
Median overall survival appears to be higher in patients who were previously treated with relapsed/refractory mantle cell lymphoma and who receive brexucabtagene autoleucel compared with standard therapy.

Brexu-cel Yields Robust Responses in Pretreated R/R Mantle Cell Lymphoma

December 6th 2023
Article

Median overall survival appears to be higher in patients who were previously treated with relapsed/refractory mantle cell lymphoma and who receive brexucabtagene autoleucel compared with standard therapy.

Oncology Peer Review On-The-Go: Minority Treatment Disparities and Clinical Trial Enrollment

Oncology Peer Review On-The-Go: Minority Treatment Disparities and Clinical Trial Enrollment

July 6th 2020
Podcast

The first episode of CancerNetwork's podcast Oncology Peer Review On-The-Go explores disparities in cancer care treatment among minorities and the significance of a representative sample in clinical trials.

T-cell Replete Cord Transplants Give Superior Outcomes in High-risk and Relapsed/refractory Pediatric Myeloid Malignancy

T-cell Replete Cord Transplants Give Superior Outcomes in High-risk and Relapsed/refractory Pediatric Myeloid Malignancy

November 22nd 2023
Article

A recent study published in Nucleus discussed the utility of T-cell replete cord blood transplant in patients with high-risk pediatric acute myeloid leukemia and myelodysplastic syndrome.

Stem Cell Transplant Approaches for Patients With Blood Cancers

Stem Cell Transplant Approaches for Patients With Blood Cancers

March 13th 2019
Podcast

Dr. Scadden discusses which blood cancer patients are eligible for stem cell transplantation, as well as the latest advances in the field.

The 3-year PFS rate for patients with MCL was 94%, and the OS rate was 97%

Maintenance Ibrutinib Improves Efficacy in MCL

November 10th 2023
Article

The 3-year PFS rate for patients with MCL was 94%, and the OS rate was 97%

Data from a phase 2 trial support lenalidomide plus rituximab as a novel treatment strategy for patients with previously untreated mantle cell lymphoma.

Lenalidomide/Rituximab Yields Enduring Benefits in Small MCL Cohort

November 6th 2023
Article

Data from a phase 2 trial support lenalidomide plus rituximab as a novel treatment strategy for patients with previously untreated mantle cell lymphoma.